Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
about
Clinical and Mechanistic Insights Into the Genetics of CardiomyopathyEfficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutationCausally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease.Time delays in the diagnosis and treatment of Fabry disease.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.Parapelvic cysts, a distinguishing feature of renal Fabry disease.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsErratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.
P2860
Q28075470-23E5CA69-2911-455D-B36E-DC9689C7EFB2Q33776219-B5C823FD-D6CC-4F68-B6EB-4E47BAC0B8B0Q33886219-8F808FB8-4E7A-4DD5-8BE9-643593E4C900Q36309032-4FB3880B-0096-4200-8620-C8DEEADA61EDQ37699393-47106D99-61F1-47BE-AF46-3A1725874C09Q38745211-2B5EBB80-959E-4CBC-A533-97F49F323FA4Q39015492-E6AB6290-8C40-49E1-A268-DD9303C043E0Q39344648-D6ED84D5-D5BB-482F-8363-85DB85AA035AQ40062693-E519DEC0-5F26-47B1-9C19-A80613DCB62AQ41200738-CFEAC7EC-38C2-44E8-ABC7-1B8DD13DFA37Q42425707-573FB236-689E-48F3-88BA-86254AD23AAEQ47118738-FE4A0948-3323-4EB1-BEF0-AA18ACB3046CQ55222984-C1AAAFA9-A2C1-46D9-BF2B-8A5A83A770BF
P2860
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@ast
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@en
type
label
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@ast
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@en
prefLabel
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@ast
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@en
P2093
P2860
P1476
Effectiveness of agalsidase al ...... mes after 10 years' treatment.
@en
P2093
Amandine Perrin
Christoph Kampmann
Michael Beck
P2860
P2888
P356
10.1186/S13023-015-0338-2
P577
2015-09-29T00:00:00Z
P5875
P6179
1036931405